Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

201. Alendronate sodium / cholecalciferol - Osteoporosis

Alendronate sodium / cholecalciferol - Osteoporosis Common Drug Review CEDAC Meeting – May 20, 2009 Page 1 of 2 Notice of CEDAC Final Recommendation – June 17, 2009 © 2009 CADTH CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION ALENDRONATE/CHOLECALCIFEROL (Fosavance ® 70/5600 – Merck Frosst Canada Ltd.) Indication: Osteoporosis Description: Fosavance 70/5600 is a fixed dose combination of alendronate, a bisphosphonate that inhibits bone resorption, and cholecalciferol (vitamin D 3 (...) ). Fosavance 70/5600 is approved by Health Canada for the treatment of osteoporosis in men and postmenopausal women. CEDAC previously reviewed Fosavance (referred to as Fosavance 70/2800 in this document), which contains alendronate 70 mg and 70 µg cholecalciferol, and recommended that it not be listed (see Fosavance Notice of CEDAC Final Recommendation on September 27, 2006). Dosage Forms: Supplied as tablets containing alendronate 70 mg and cholecalciferol 140 µg (5600 IU vitamin D 3 ). The recommended

2009 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

202. Bone health. In: Menopause and osteoporosis update 2009.

Bone health. In: Menopause and osteoporosis update 2009. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline

2009 Society of Obstetricians and Gynaecologists of Canada

203. Mood, memory, and cognition. In: Menopause and osteoporosis update 2009.

Mood, memory, and cognition. In: Menopause and osteoporosis update 2009. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National

2009 Society of Obstetricians and Gynaecologists of Canada

204. Urogenital health. In: Menopause and osteoporosis update 2009.

Urogenital health. In: Menopause and osteoporosis update 2009. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline

2009 Society of Obstetricians and Gynaecologists of Canada

205. Hormone therapy and breast cancer. In: Menopause and osteoporosis update 2009.

Hormone therapy and breast cancer. In: Menopause and osteoporosis update 2009. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding

2009 Society of Obstetricians and Gynaecologists of Canada

206. Cardiovascular disease. In: Menopause and osteoporosis update 2009.

Cardiovascular disease. In: Menopause and osteoporosis update 2009. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National

2009 Society of Obstetricians and Gynaecologists of Canada

207. Vasomotor symptoms. In: Menopause and osteoporosis update 2009.

Vasomotor symptoms. In: Menopause and osteoporosis update 2009. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline

2009 Society of Obstetricians and Gynaecologists of Canada

208. Hyperkyphosis predicts mortality independent of vertebral osteoporosis in older women. Full Text available with Trip Pro

Hyperkyphosis predicts mortality independent of vertebral osteoporosis in older women. Excessive kyphosis may be associated with earlier mortality, but previous studies have not controlled for clinically silent vertebral fractures, which are a known mortality risk factor.To determine whether hyperkyphosis predicts increased mortality independent of vertebral fractures.Prospective cohort study.Four clinical centers in Baltimore County, Maryland; Portland, Oregon; Minneapolis, Minnesota (...) and other predictors of mortality, including such osteoporosis-related factors as low bone density, moderate and severe prevalent vertebral fractures, and number of prevalent vertebral fractures, women with greater kyphosis were at increased risk for earlier death (relative hazard per SD increase, 1.15 [CI, 1.01 to 1.30]; P = 0.029). On stratification by prevalent vertebral fracture status, only women with prevalent fractures were at increased mortality risk from hyperkyphosis, independent of age, self

2009 Annals of Internal Medicine

209. Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis (Abstract)

Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis Bone loss is often observed in patients with ulcerative colitis, particularly if they require glucocorticoids.To determine whether the bisphosphonate, alendronate, is safe and effective in preserving bone mass compared to the active vitamin D3, alfacalcidol, in ulcerative colitis patients receiving glucocorticoids.Thirty-nine patients with ulcerative colitis

2009 EvidenceUpdates Controlled trial quality: uncertain

210. Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial Full Text available with Trip Pro

Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial In a randomized trial of patients with hip fractures, we previously demonstrated that a hospital-based case manager could increase rates of appropriate osteoporosis treatment to 51% compared with 22% for usual care (P < .001). Alongside that trial, we conducted an economic analysis.Patients with hip fractures were randomized to usual care (n = 110) or a case (...) a case manager for patients with hip fractures increased rates of appropriate osteoporosis treatment. The intervention dominated usual care, and the analysis suggests that systems implementing an intervention similar to ours should expect to see a reduction in fractures, gains in life expectancy, and substantial cost savings.clinicaltrials.gov Identifier: NCT00175175.

2009 EvidenceUpdates Controlled trial quality: uncertain

211. Technologies for the identification of osteoporosis

Technologies for the identification of osteoporosis Technologies for the identification of osteoporosis Technologies for the identification of osteoporosis Amicosante AMV, Bernardini F, Cavallo A, Cerbo M, Jefferson T, Lo Scalzo A, Ratti M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Amicosante AMV, Bernardini F, Cavallo A, Cerbo M (...) , Jefferson T, Lo Scalzo A, Ratti M. Technologies for the identification of osteoporosis. Rome: Agenzia nazionale per i servizi sanitari regionali. 2009 Authors' objectives The objectives of this report are: to identify the most widely used technologies for the identification and assessment of osteoporosis in the target population in our country; to accurately describe the acquisition and use of the technology and its alternative in the Italian context; to assess the evidence for the chosen technologies

2009 Health Technology Assessment (HTA) Database.

212. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. Full Text available with Trip Pro

Denosumab for prevention of fractures in postmenopausal women with osteoporosis. Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-kappaB ligand (RANKL) that blocks its binding to RANK, inhibiting the development and activity of osteoclasts, decreasing bone resorption, and increasing bone density. Given its unique actions, denosumab may be useful in the treatment of osteoporosis.We enrolled 7868 women between the ages of 60 and 90 years who had a bone (...) % CI, 0.67 to 0.95; P=0.01)--a relative decrease of 20%. There was no increase in the risk of cancer, infection, cardiovascular disease, delayed fracture healing, or hypocalcemia, and there were no cases of osteonecrosis of the jaw and no adverse reactions to the injection of denosumab.Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis. (ClinicalTrials.gov number, NCT00089791

2009 NEJM Controlled trial quality: predicted high

213. Calcium and bone health: position statement for the Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia and the Endocrine Society of Australia Full Text available with Trip Pro

Calcium and bone health: position statement for the Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia and the Endocrine Society of Australia Calcium and bone health: position statement for the Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia and the Endocrine Society of Australia | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type (...) Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Calcium and bone health: position statement for the Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia and the Endocrine Society of Australia Kerrie M Sanders, Caryl A Nowson, Mark A Kotowicz, Kathryn Briffa, Amanda Devine and Ian R Reid Med J Aust

2009 MJA Clinical Guidelines

214. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review Full Text available with Trip Pro

Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review Gleeson T, Iversen MD, Avorn J, Brookhart AM, Katz JN, Losina E, May F, Patrick AR, Shrank WH, Solomon DH CRD summary The authors concluded that few (...) interventions designed to improve adherence and persistence with osteoporosis medications were efficacious and that no clear trends in successful intervention techniques were identified in this small sample of studies. These conclusions reflect the evidence presented, but the poor quality of included studies and the potential for publication and language bias should be borne in mind. Authors' objectives To evaluate the effectiveness of interventions designed to improve adherence and persistence

2009 DARE.

215. The Osteoporosis Self-Assessment Tool versus alternative tests for selecting postmenopausal women for bone mineral density assessment: a comparative systematic review of accuracy

The Osteoporosis Self-Assessment Tool versus alternative tests for selecting postmenopausal women for bone mineral density assessment: a comparative systematic review of accuracy Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

216. Pharmacological management of osteoporosis in nursing home populations: a systematic review

Pharmacological management of osteoporosis in nursing home populations: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

217. Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies

Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

218. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis

Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

219. Current status of research on osteoporosis in COPD: a systematic review

Current status of research on osteoporosis in COPD: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

220. A study to establish the feasibility of a trial that would investigate the clinical and cost-effectiveness of stopping bisphosphonate treatment after 5 years in post-menopausal women with osteoporosis who have already had a fracture

A study to establish the feasibility of a trial that would investigate the clinical and cost-effectiveness of stopping bisphosphonate treatment after 5 years in post-menopausal women with osteoporosis who have already had a fracture A study to establish the feasibility of a trial that would investigate the clinical and cost-effectiveness of stopping bisphosphonate treatment after 5 years in post-menopausal women with osteoporosis who have already had a fracture A study to establish (...) the feasibility of a trial that would investigate the clinical and cost-effectiveness of stopping bisphosphonate treatment after 5 years in post-menopausal women with osteoporosis who have already had a fracture Stevenson MD, Oakley JE, Lloyd Jones M, Brennan A, Compston JE, McCloskey EV, Selby PL Citation Stevenson MD, Oakley JE, Lloyd Jones M, Brennan A, Compston JE, McCloskey EV, Selby PL. A study to establish the feasibility of a trial that would investigate the clinical and cost-effectiveness of stopping

2009 Health Technology Assessment (HTA) Database.